<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01186861</url>
  </required_header>
  <id_info>
    <org_study_id>OSI-906-205</org_study_id>
    <secondary_id>2010-020916-12</secondary_id>
    <nct_id>NCT01186861</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-controlled Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Erlotinib Plus Placebo in Patients With Nonprogression Following Four Cycles of 1st-line Platinum-based Chemotherapy for Advanced NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, randomized, double-blind, placebo-controlled, phase 2 study with a 1:1
      randomization scheme.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adult patients with advanced Non-small Cell Lung Cancer (NSCLC) and nonprogression after
      platinum-based chemotherapy will be randomized 1:1 to receive either OSI-906 plus erlotinib
      or placebo plus erlotinib.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Progression Free Survival (PFS) of maintenance OSI-906 plus erlotinib, or placebo plus erlotinib in patients with nonprogression following four cycles of first-line platinum-based chemotherapy for advanced NSCLC in the overall population</measure>
    <time_frame>22 months</time_frame>
    <description>PFS is defined as the time from randomization to disease progression based on RECIST v1.1 or death due to any cause whichever comes first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>27 months</time_frame>
    <description>The time from the date of randomization until the documented date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control Rate (DCR)</measure>
    <time_frame>27 months</time_frame>
    <description>The proportion of patients with a best overall response of continued Complete Response (CR), CR, Partial Response (PR), OR Stable Disease (SD) based on RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response rate (ORR)</measure>
    <time_frame>27 months</time_frame>
    <description>The proportion of patients with a best overall response of CR or PR based on RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response upgrade rate (RUR)</measure>
    <time_frame>27 months</time_frame>
    <description>The proportion of patients with a response upgrade</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>27 months</time_frame>
    <description>The time from the date of the first documented response (CR/PR) to documented progression or death due to underlying cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed through physical examination, vital signs, clinical laboratory tests, electrocardiograms (ECG) and Adverse Events</measure>
    <time_frame>27 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">205</enrollment>
  <condition>Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy</condition>
  <arm_group>
    <arm_group_label>Arm A: OSI-906 plus erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OSI-906 150 mg twice daily (BID) starting on Day 1; erlotinib 150 mg once daily (QD) starting on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: placebo plus erlotinib</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo BID starting on Day 1: erlotinib 150 mg QD starting on Day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OSI-906</intervention_name>
    <description>Tablet administered with food and with up to 200 mL of water</description>
    <arm_group_label>Arm A: OSI-906 plus erlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib</intervention_name>
    <description>Tablet administered at least 2 hours after food with up to 200 mL of water</description>
    <arm_group_label>Arm A: OSI-906 plus erlotinib</arm_group_label>
    <arm_group_label>Arm B: placebo plus erlotinib</arm_group_label>
    <other_name>OSI-774</other_name>
    <other_name>Tarceva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Tablet administered at least 2 hours after food with up to 200 mL of water</description>
    <arm_group_label>Arm B: placebo plus erlotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed locally advanced or metastatic stage IIIB or IV NSCLC

          -  Have experienced Complete Response (CR), Partial Response (PR) or Stable Disease (SD)
             following completion of 4 cycles of first-line platinum-based chemotherapy and are not
             progressing at time of entry into study (prior completed first-line combination
             bevacizumab therapy is permitted; however, current use of maintenance bevacizumab is
             not permitted. A maximum interval of 28 days between the last day of the treatment
             cycle and randomization

          -  Patient has recovered from prior chemotherapy-related toxicity to ≤ grade 2

          -  EGFR mutation status must be confirmed for participation in the study. EGFR analysis
             can be performed either by central or local laboratory. If analysis is done locally,
             verifiable documentation confirming the EGFR mutation status must be submitted for
             review and approval by APGD prior to randomization. If no local result is available,
             formalin-fixed, paraffin-embedded archival tissue representative of the tumor or in
             the absence of archival tissue, a fresh tumor tissue sample of sufficient size to
             perform EGFR mutation analysis must be submitted centrally. Results of the central
             analysis must be available prior to randomization. Additionally, subjects should
             provide tissue blocks centrally for biomarker analysis whenever possible. Ideal tissue
             requirement: block with ≥5 mm2 tumor area sufficient to provide four 4-micron, and
             five 10-micron sections)

          -  Measurable disease (for those patients with PR or SD after first-line platinum-based
             chemotherapy) according to Response Evaluation Criteria in Solid Tumors (RECIST)
             (version 1.1)

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status(PS) 0 - 1

          -  Previous adjuvant or neo-adjuvant treatment is permitted

          -  Must be able to take oral medication

          -  Fasting glucose ≤ 150 mg/dL (8.3 mmol/L). Concurrent use of non-insulinotropic
             antihyperglycemic therapy is permitted if the dose has been stable for ≥ 4 weeks at
             the time of randomization

          -  Adequate hematopoietic, hepatic, and renal function defined as follows:

               -  Neutrophil count ≥ 1.5 x 109/L

               -  Platelet count ≥ 100 x 109/L

               -  Bilirubin ≤ 1.5 x Upper Limit of Normal (ULN)

               -  AST and ALT ≤ 2.5 x ULN, or ≤ 5 x ULN if patient has documented liver metastases

               -  Serum creatinine ≤ 1.5 x ULN

          -  Potassium, magnesium and calcium within normal limits (supplementation and retesting
             is permitted)

        Female patient must be either:

          -  Of non child bearing potential:

               -  post-menopausal (defined as at least 1 year without any menses) prior to
                  Screening, or

               -  documented surgically sterile or status post hysterectomy (at least 1 month prior
                  to Screening)

          -  Or, if of childbearing potential:

               -  must have a negative urine pregnancy test at Screening, and

               -  must use two forms of birth control (one of which must be a barrier method)
                  starting at Screening and throughout the study period and for 30 days after final
                  study drug administration

          -  Female patient must not be breastfeeding at Screening or during the study period and
             for 30 days after final study drug administration

          -  Female patient must not donate ova starting at Screening and throughout the study
             period and for 30 days after final study drug administration

          -  Male patient and their female spouse/partners who are of childbearing potential must
             be using highly effective contraception consisting of two forms of birth control (one
             of which must be a barrier method) starting at Screening and continue throughout the
             study period and for 30 days after final study drug administration

          -  Male patient must not donate sperm starting at Screening and throughout the study
             period and for at least 30 days after final study drug administration

          -  Prior radiation therapy is permitted provided patients have recovered from acute toxic
             effects of radiotherapy prior to randomization. A minimum of 28 days must have elapsed
             between the end of radiotherapy and randomization

          -  Prior surgery is permitted provided that the surgery was performed 21 days prior to
             randomization and adequate wound healing has occurred prior to randomization

          -  Patients must provide written (signed) informed consent to participate in the study
             and for use of tumor tissues

        Exclusion Criteria:

          -  Prior exposure to agents directed at the Human Epidermal Receptor (HER) axis (eg,
             erlotinib, gefitinib, cetuximab, and trastuzumab)

          -  Malignancies other than NSCLC within past 3 years (exceptions if curatively treated:
             basal or squamous cell carcinoma of skin; locally advanced prostate cancer; ductal
             carcinoma in situ of breast; in situ cervical carcinoma; and superficial bladder
             cancer)

          -  Type 1 diabetes mellitus or Type 2 diabetes mellitus currently requiring
             insulinotropic or insulin therapy

          -  Prior insulin-like growth factor receptor (IGF-1R)

          -  Prior investigational agent within 21 days prior to randomization

          -  Concurrent use of maintenance bevacizumab

          -  History of poorly controlled gastrointestinal disorders that could affect the
             absorption of study drug (eg, Crohn's disease, ulcerative colitis, etc)

          -  History (within last 180 days) of significant cardiovascular disease unless the
             disease is well-controlled. Significant cardiac disease includes second/third degree
             heart block; clinically significant ischemic heart disease; superior vena cava (SVC)
             syndrome; poorly controlled hypertension; congestive heart failure of New York Heart
             Association (NYHA) Class II or worse (slight limitation of physical activity;
             comfortable at rest, but ordinary physical activity results in fatigue, palpitation,
             or dyspnea)

          -  History of arrhythmia (multifocal premature ventricular contractions [PVCs], bigeminy,
             trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) that is
             symptomatic or requires treatment (≥ grade 3), left bundle branch block (LBBB), or
             asymptomatic sustained ventricular tachycardia are not allowed. Patients with atrial
             fibrillation controlled by medication are not excluded

          -  Mean QTcF interval &gt; 450 msec based on independent central reviewer analysis of
             screening visit ECGs

          -  Use of drugs that have a known risk of causing Torsades de Pointes (TdP) are
             prohibited within 14 days prior to randomization

          -  Use of the potent CYP1A2 inhibitors ciprofloxacin and fluvoxamine. Other less potent
             CYP1A2 inhibitors/inducers are not excluded

          -  Use of potent CYP3A4 inhibitor such as ketoconazole, clarithromycin, atazanavir,
             indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin,
             troleandomycin (TAO), or voriconazole

          -  Use of proton pump inhibitors such as omeprazole. Use of H2-receptor antagonists such
             as ranitidine are not excluded

          -  History of cerebrovascular accident (CVA) within 180 days prior to randomization or
             that resulted in ongoing neurologic instability

          -  Active infection, serious underlying medical condition (including any type of active
             seizure disorder within 12 months prior to randomization), or serious chronic illness
             that would impair the ability of the patient to receive study drug

          -  History of any psychiatric or neurologic condition that might impair the patient's
             ability to understand or to comply with the requirements of the study or to provide
             informed consent

          -  Pregnant or breast-feeding females

          -  Symptomatic brain metastases that are not stable, require steroids, or that have
             required radiation and/or other related treatment (e.g., anti-epileptic medication)
             within 21 days prior to randomization

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to study drug

          -  Participated in any interventional clinical study or has been treated with any
             investigational drugs within 30 days or 5 half lives whichever is longer, prior to the
             initiation of Screening or during the course of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>10007: Baptist Cancer Institute</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>10001: Hematology Oncology Associates of the Treasure Coast</name>
      <address>
        <city>Port St. Lucie</city>
        <state>Florida</state>
        <zip>34952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>10002: Phoebe Putney Memorial Hospital</name>
      <address>
        <city>Albany</city>
        <state>Georgia</state>
        <zip>31701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>10008: Rush Presbyterian-Saint Luke's Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>10011: Maine Center for Cancer Medicine and Blood Disorders</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>10004: Moses H. Cone Regional Cancer Center</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 10010 Piedmont Hematlogy Oncology Associates, PLLC</name>
      <address>
        <city>Winston - Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>55003: Centro Regional Integrado de Oncologia</name>
      <address>
        <city>Fortaleza</city>
        <state>Ceara</state>
        <zip>60336-550</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>55015: Centro de Pesquisa Clínica em Oncologia-CPCO</name>
      <address>
        <city>Cachoeiro de Itapemirim</city>
        <state>Espirito Santo</state>
        <zip>29308-014</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>55016:Centro Brasileiro de Radioterapia Oncologia e Mastologia</name>
      <address>
        <city>Goiânia</city>
        <state>Goias</state>
        <zip>74605-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>55006: Hospital de Caridade de Ijuí</name>
      <address>
        <city>Ijuí</city>
        <state>Rio Grande Do Sul</state>
        <zip>98700-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>55011: CEPON-Centro de pesquisas Oncologicas</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>55013: Clínica de Oncologia de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90430-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>55014: Hospital São Lucas - PUCRS</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>55001: Clínica de Neoplasias Litoral</name>
      <address>
        <city>Itajaí</city>
        <state>Santa Catarina</state>
        <zip>88301-220</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>55008: Irmandade da Santa Casa de Misericórdia de Piracicaba</name>
      <address>
        <city>Piracicaba</city>
        <state>Sao Paula</state>
        <zip>13419-155</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>55005: Fundação Pio XII, Hospital de Câncer de Barretos</name>
      <address>
        <city>Barretos</city>
        <state>Sao Paulo</state>
        <zip>14784-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>55012: Instituto Ribeirãopretano de Combate ao Câncer</name>
      <address>
        <city>Ribeirão Preto</city>
        <state>Sao Paulo</state>
        <zip>14015-130</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>55004: Hospital Universitário de Brasília-HUB</name>
      <address>
        <city>Brasilia</city>
        <zip>70840-91</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>55002: Instituto Nacional do Câncer</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20231-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>55007:Instituto do Câncer de São Paulo Octavio Frias de Oliveira</name>
      <address>
        <city>São Paulo</city>
        <zip>01246-00</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>11001: RSM Durham Regional Cancer Centre</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1G2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>11004: Ottawa Regional Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K2H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>11006: Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>11002: Saint Joseph Health Center</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6R 1B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>49001: Thoraxklink Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>49012: Saint Vincentius-Kliniken Karlsruhe</name>
      <address>
        <city>Karlsruhe</city>
        <state>Baden-Wuerttemberg</state>
        <zip>76137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>49006: Fachklinik für Lungenkrankheiten</name>
      <address>
        <city>Immenhausen</city>
        <state>Hessen</state>
        <zip>34376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>49015: Klinikum Kassel</name>
      <address>
        <city>Kassel</city>
        <state>Hessen</state>
        <zip>34125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>49011: Klinikum Dortmund gGmbH</name>
      <address>
        <city>Dortmund</city>
        <state>Nordrhein-westfalen</state>
        <zip>44145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>49002: Lungenklinik Hemer</name>
      <address>
        <city>Hemer</city>
        <state>Nordrhein-Westfalen</state>
        <zip>58675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>49005: Johannes-Wesling-Klinikum</name>
      <address>
        <city>Minden</city>
        <state>Nordrhein-Westfalen</state>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>49013: Katholisches Klinikum Mainz, Sankt Hildegardis-Krankenhaus</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>49009: Universitätsklinikum des Saarlandes</name>
      <address>
        <city>Homburg/Saar</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>49003: Krankenhaus Großhansdorf</name>
      <address>
        <city>Großhansdorf</city>
        <state>Schleswig-Holstein</state>
        <zip>22977</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>49010: Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Lübeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>49014: Charite Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>49008: Kliniken der Stadt Köln gGmbH</name>
      <address>
        <city>Koln</city>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>82007: Dong-A University Medical Center</name>
      <address>
        <city>Busan</city>
        <zip>602-715</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>82001: Saint Vincent Hospital</name>
      <address>
        <city>Gyeonggi-Do</city>
        <zip>442-723</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>82006: Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun, Jeollanam-do</city>
        <zip>519-763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>82008: Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <zip>400-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>82004: Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>82003: Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>82005: Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>82002: Seoul Saint Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137-040</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>48006: Katedra I Klinika Chorob Pluc Slaskiej AM, Dept. of Pulmonology</name>
      <address>
        <city>Wroclaw</city>
        <state>Dolnoslaskie</state>
        <zip>53-439</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>48008:Wojewódzki Szpital Zespolony im. L. Rydygiera w Toruniu Szpital Dzieciecy</name>
      <address>
        <city>Torun</city>
        <state>Kujawsko-pomorskie</state>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>48002: SPZOZ, Wojewódzki Szpital Zespolony w Elblagu</name>
      <address>
        <city>Elblag</city>
        <state>Warminsko-mazurskie</state>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>48005: Specjalistyczny Szpital im. Prof. Alfreda Sokołowskiego</name>
      <address>
        <city>Szczecin</city>
        <zip>70-891</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>40005: Spitalul Judetean Alba Iulia</name>
      <address>
        <city>Alba Iulia</city>
        <state>Alba</state>
        <zip>510077</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>40002: Institutul Oncologic &quot;Prof. Dr. I. Chiricuta&quot;</name>
      <address>
        <city>Cluj-Napoca</city>
        <state>Cluj</state>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>40003: Institutul Oncologic &quot;Prof. Dr. I. Chiricuta&quot;</name>
      <address>
        <city>Cluj-Napoca</city>
        <state>Cluj</state>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>40006: Oncolab SRL</name>
      <address>
        <city>Craiova</city>
        <state>Dolj</state>
        <zip>200385</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>40001: Spitalul Judetean de Urgenta Baia Mare</name>
      <address>
        <city>Baia Mare</city>
        <state>Maramures</state>
        <zip>4800</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>40007: Policlinica de Diagnostic Rapid</name>
      <address>
        <city>Brasov</city>
        <zip>500366</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>40004: Spitalul Municipal &quot;Dr. Alexandru Simionescu&quot; Hunedoara</name>
      <address>
        <city>Hunedoara</city>
        <zip>331057</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>70010: Republican Clinical Oncologic Dispensary of Ministry of health of Republic Tatarstan</name>
      <address>
        <city>Kazan</city>
        <state>Tatarstan</state>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>70002: Regional Oncology Centre</name>
      <address>
        <city>Chelaybinsk</city>
        <zip>454087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>70007: Leningrad Regional Clinical Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>70009: Saint-Petersburg State Medical University n.a. ac. I.P. Pavlov, Dept. of Thoracal Oncology</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>70011: Saint-Petersburg State Medical University n.a. ac. I.P. Pavlov, Dept. of Thoracal Oncology</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>44007: Bristol Haematology and Oncology Centre</name>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>44003: Saint James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>44002: Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <state>England</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>44005: University College London</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>NW1 2PQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>44001: Christie Hospital NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>44004: Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <state>England</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>44006: Ninewells Hospital</name>
      <address>
        <city>Dundee</city>
        <state>Scotland</state>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2010</study_first_submitted>
  <study_first_submitted_qc>August 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2010</study_first_posted>
  <disposition_first_submitted>June 19, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>June 19, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 23, 2014</disposition_first_posted>
  <last_update_submitted>April 7, 2015</last_update_submitted>
  <last_update_submitted_qc>April 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>Erlotinib</keyword>
  <keyword>OSI-906</keyword>
  <keyword>Placebo</keyword>
  <keyword>Platinum-based chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

